Modality
Bispecific Ab
MOA
C5i
Target
IL-17A
Pathway
Innate Imm
HS
Development Pipeline
Preclinical
~Apr 2018
→ ~Jul 2019
Phase 1
~Oct 2019
→ ~Jan 2021
Phase 2
Apr 2021
→ Jun 2026
Phase 2Current
NCT03017712
2,194 pts·HS
2021-04→2026-06·Completed
2,194 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-06-082mo awayPh3 Readout· HS
Trial Timeline
Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3
P2/3
Complet…
Catalysts
Ph3 Readout
2026-06-08 · 2mo away
HS
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03017712 | Phase 2/3 | HS | Completed | 2194 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| DSN-2247 | Daiichi Sankyo | NDA/BLA | EZH2 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| RVM-7089 | Revolution Medicines | Phase 3 | IL-17A | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | GPRC5D | |
| XEN-577 | Xenon Pharma | Phase 2/3 | C5 | |
| Adagrarapivir | Ideaya Bio | Phase 1/2 | IL-17A | |
| Polazanubrutinib | Tango Ther | Phase 1 | IL-17A | |
| EXA-4696 | Exscientia | Phase 2/3 | KRASG12C |